|
|
RAS blockade in the real world: From clinical trial data to challenges in daily hypertension management
|
|
|
|
LIFE: Design and Dosing Titration to target blood pressure: <140 / <90 mmHg
|
|
|
|
LIFE: Blood Pressure During Follow-up
|
|
|
|
LIFE: Primary Composite Endpoint
|
|
|
|
LIFE: Fatal/Non-fatal Stroke
|
|
|
|
LIFE: ISH – Fatal/Non-fatal Stroke
|
|
|
|
LIFE Atrial Fibrillation: Losartan vs. Atenolol Reduces New Onset AF/Flutter
|
|
|
|
SCOPE: Study Design
|
|
|
|
SCOPE: Baseline Characteristics
|
|
|
|
SCOPE-ISH: Fatal and Non-fatal Strokes
|
|
|
|
VALUE: Design Elective Titration to Target BP (<140/90 mmHg)
|
|
|
|
VALUE: Systolic Blood Pressure in Study
|
|
|
|
VALUE: Primary Composite Cardiac Endpoint
|
|
|
|
Reduced Incidence of New Onset Atrial Fibrillation With ARB: the VALUE Trial
|
|
|
|
VALUE: New-onset Diabetes Valsartan vs Amlodipine
|
|
|
|
CASE-J: Dosage Schedule (n=4728) (Candesartan Antihypertensive Survival Evaluation in Japan)
|
|
|
|
Blood Pressure Changes
|
|
|
|
Primary Composite Endpoints Comparison of Cardiovascular Events
|
|
|
|
CASE-J: New-onset Diabetes
|
|
|
|
Binding Ability to the AT1 Receptor
|
|
|
|
The Real Life Study: Hypothesis and Aim
|
|
|
|
Study Cites in Uppsala Area, Sweden
|
|
|
|
Health Care in Sweden
|
|
|
|
Extraction Method
|
|
|
|
Data Extraction in Primary Care
|
|
|
|
Prescription Patterns at Study Centers
|
|
|
|
Included Patients Per Year
|
|
|
|
Selection Method
|
|
|
|
Baseline Characteristics
|
|
|
|
Up-titration of ARB
|
|
|
|
Ratio (candesartan/losartan)
|
|
|
|
Follow-up Time (months)
|
|
|
|
Blood Pressure Reduction
|
|
|
|
ARB Titration
|
|
|
|
Concomitant Medication
|
|
|
|
Limitations
|
|
|
|
Conclusion – Conduct of Real Life
|
|
|
|
CVD Risk
|
|
|
|
Risk of Separate Endpoints
|
|
|
|
Hazard Ratio
|
|
|
|
Additional Adjustments
|
|
|
|
REAL LIFE: Conclusions
|
|
|
|
Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure
|
|
|
|
|
|
|
Overall Survival
|
|
|
|
Survival Women
|
|
|
|
EF >40%
|
|
|
|
NYHA I
|
|
|
|
Conclusions Swedish Heart Failure Registry Study
|
|
|
|
Meta-Analysis Cancer Incidence ARBs
|
|
|
|
Cancer in 15 ARB Trials : ARB vs. non ARB
|
|
|
|
Overall Conclusions
|
|
Share this page with your colleagues and friends: